The Danish company XGX Pharma has been sold to Unimedic Pharma AB, a wholly owned subsidiary of the Swedish listed company MedCap AB. The purchase price is up to DKK 275 million. The management who has historically been majority owners will continue in the company.
XGX Pharma is a fast-growing specialty pharmaceutical company with seven products on the market, primarily in the Nordic region, within specialty Gx pharmaceuticals. XGX Pharma has a strong and very promising pipeline of 20 niche products in either late-stage development or registration phase. Expected product launches for this pipeline will be during the coming years, and, consequently, the company expects significant growth. XGX Pharma’s net sales for the last 12 months amounted to DKK 51 million, which corresponds to a growth of 91% compared to the same period last year.
The acquisition of XGX Pharma strengthens Unimedic Pharma as one of the leading Nordic specialty pharmaceutical companies with higher profitability, organic growth and a broad pipeline of niche products.
MedCap is listed on Nasdaq Stockholm and focuses on profitable, market-leading niche companies within the life science industry.
The transaction is subject to the usual public authority approvals in Denmark and is expected to be completed in the beginning of Q3 2025.
Accura advised XGX Pharma, the sellers and the management in connection with the transaction.
For further information, please read the press release.